Clinical Trials · NCT05153772
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Orano Med LLC
- Enrollment
- 69
- Start date
- Dec 2021
- Locations
- 4 sites, United States
- Primary endpoint
- Measurement of the objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.